1. Greene DA, Sima AF, Pfeifer MA, Albers JW. Diabetic neuropathy. Annu Rev Med 41;303-317, 1990.

2. Pirart J. Diabetes mellitus and its degenerative complications: a prospective study of 4400 patients observed between 1947 and 1973. Part 2. Diabetes Care 1978;1:252-294.

3. Vinik AI, Liuzze FJ, Holland MT, Stansberry KB, LeBean JM, Coleb LB. Diabetic neuropathies. Diabetes Care 1992;15:1926-1975.

4. Sima AAF. Pathological definition and evaluation of diabetic neuropathy and clinical correlations. Can J Neurol Sci 1994;21(Suppl 4):513-517.

5. Sima AA, Cherian PV. Neuropathology of diabetic neuropathy and its correlations with neurophysiology. Clin Neurosci 1997;4:359-364.

6. Thomas PK. Classification, differential diagnosis, and staging of diabetic peripheral neuropathy. Diabetes 1997;46(Suppl 2):S54-S57.

7. Duby JJ, Campbell RK, Setter SM, White JR, Rasmussen KA. Diabetic neuropathy: an intensive review. Am J Health Syst Pharm 2004;61:160-173.

8. Greene DA, Sima AAF, Stevens MJ, Feldman EL, Lattimer SA. Complications: neuropathy, pathogenetic considerations. Diabetes Care 1992;15:1902-1925.

9. Annunzio d' G, Malvezzi F, Vitali L, et al. A 3-19 year follow up study on diabetic retinopathy in patients diagnosed in childhood and treated with conventional therapy. Diabetic Med 1997;14:951-955.

10. D'Angio CT, Ambati J, Phelps DL. Do urinary levels of vascular endothelial growth factors predict proliferative retinopathy? Curr Eye Res 2001;22:90.

11. Kalter-Leibovici O, Leibovici L, Loya N, et al. The development and progression of diabetic retinopathy in type 1 diabetic patients: a cohort study. Diabetic Med 1997;14:858-866.

12. Cohen RA, Hennekens CH, Christen WG, et al. Determinants of retinopathy progression in type 1 diabetes mellitus. Am J Med 1999;107:45-51.

13. DCCT Research Group. The absence of a glycaemic threshold for the development of long term complications: the perspective of the Diabetes Control and Complications Trial. Diabetes 1996;45:1289-1298.

14. Forst T, Kunt T, Pf utzner A, Beyeer J, Wahren J. New aspects on biological activity of C-peptide in IDDM patients. Exp Clin Enocriol 1998;106:270-276.

15. Rich SS, Freedman BI, Bowden DW. Genetic epidemiology of diabetic complications. Diabetic Revs 1997;5:165-173.

16. DCCT Research Group. The effect of intensive treatment of diabetes on the development and progression of long term complications in insulin dependent diabetes mellitus. New Engl J Med 1993;329;977-986.

17. DCCT Research Group. The relationship of glycaemic exposure (HbA1c) to the risk of development and progression of retinopathy in the diabetes controls and complications trial. Diabetes 1995;44:968-983.

18. Krolewski AS, Doria A, Magre J, Warram JH, Housman D. Molecular genetic approaches to the identification of genes involved in the development of nephropathy in insulin-dependent diabetes mellitus. J Am Soc Nephrol 1992;3(4 Suppl):S9-17.

19. Krolewski AS. Genetics of diabetic nephropathy: evidence for major and minor gene effects. Kidney Int 1999;55:1582-1596.

20. DCCT Research Group. Clustering of long term complications in families with diabetes in the diabetes control and complications trial. Diabetes 1997;46:1829-1839.

21. Connolly SB, Sadlier D, Kieran NE, Doran P, Brady HR. Transcriptome profiling and the pathogenesis of diabetic complications. J Am Soc Nephrol 2003;14(Suppl 3):S279-S283.

22. Antonellis A, Rogus JJ, Canani LH, et al. A method for developing high-density SNP maps and its application at the type 1 angiotensin II receptor (AGTR1) locus. Genomics 2002; 79:326-332.

23. Imperatore G, Hanson RL, Pettitt DJ, Kobes S, Bennett PH, Knowler WC. Sib-pair linkage analysis for susceptibility genes for microvascular complications among Pima Indians with type 2 diabetes. Pima Diabetes Genes Group. Diabetes 1998;47:821-830.

24. Freedman BI, Rich SS, Yu H, Roh BH, Bowden DW. Linkage heterogeneity of end-stage renal disease on human chromosome 10. Kidney Int 2002;62:770-774.

25. Hunt SC, Hasstedt SJ, Coon H, Camp NJ, Cawthon RM, Wu LL, Hopkins PN. Linkage of creatinine clearance to chromosome 10 in Utah pedigrees replicates a locus for end-stage renal disease in humans and renal failure in the fawn-hooded rat. Kidney Int 2002; 62:1143-1148.

26. Vardarli I, Baier LJ, Hanson RL, et al. Gene for susceptibility to diabetic nephropathy in type 2 diabetes maps to 18q22.3-23. Kidney Int 2002;62:2176-2183.

27. Tanaka N, Babazono T, Saito S, et al. Association of solute carrier family 12 (sodium/ chloride) member 3 with diabetic nephropathy, identified by genome-wide analyses of single nucleotide polymorphisms. Diabetes 2003;52:2848-2853.

28. Rogus JJ, Warram JH, Krolewski AS. Genetic studies of late diabetic complications: the overlooked importance of diabetes duration before complication onset. Diabetes 2002;51(6): 1655-1662.

29. Williamson JR, Chang K, Frangos M, et al. Hyperglycemic pseudohypoxia and diabetic complications. Diabetes 1993;42:801-813.

30. Stevens MJ, Dannanberg J, Feldman EL, et al. The linked roles of nitric oxide, aldose reductase, and (Na+, K+)-ATPase in the slowing bof nerve conduction in the streptozotocin diabetic rat. J Clin Invest 1994;94:853-859.

31. Cameron NE, Cotter MA, Hohman TC. Interactions between essential fatty acid, prostanoid, polyol pathway and nitric oxide mechanisms in the neurovascular deficit of diabetic rats. Diabetologia 1996;39:172-182.

32. Cameron NE, Cotter MA, Basso M, Hohman TC. Comparison of the effects of inhibitors of aldose reductase and sorbitol dehydrogenase on neurovascular function, nerve conduction and tissue polyol pathway metabolites in streptozotocin-diabetic rats. Diabetologia 1997;40:271-281.

33. Cameron NE, Cotter MA, Jack AM, Basso MD, Hohman TC. Protein kinase C effects on nerve fuction, perfusion, Na+, K+-ATPase activity and glutathione contents in diabetic rats. Diabetologia 1999;42:1120-1130.

34. Keogh RJ, Dunlop ME, Larkins RG. Effect of inhibition of aldose reductase on glucose of flux, diacylglycerol formation, protein kinase C, and phospholipase A2 activation. Metabolism 1997;46:41-47.

35. Price SA, Agthong S, Middlemas AB, Tomlinson DR. Mitogen-activated protein kinase p38 mediates reduced nerve conduction velocity in experimental diabetic neuropathy: interactions with aldose reductase. Diabetes 2004;53:1851-1856.

36. Yagihashi S, Yamagishi SI, Wada Ri R, et al. Neuropathy in diabetic mice overexpressing human aldose reductase and effects of aldose reductase inhibitor. Brain 2001; 124(Pt 12):2448-2458.

37. Song Z, Fu DT, Chan YS, Leung S, Chung SS, Chung SK. Transgenic mice overexpressing aldose reductase in Schwann cells show more severe nerve conduction velocity deficit and oxidative stress under hyperglycemic stress. Mol Cell Neurosci 2003;23(4):638-647.

38. Obrosova IG. How does glucose generate oxidative stress in peripheral nerve? Int Rev Neurobiol 2002;50:3-35.

39. Van der Jagt DL, Robinson B, Taylor KK, Hunsaker LA. Reduction of trioses by NADPH-dependent aldo-keto reductases. Aldose reductase, methylglyoxal and diabetic complications. J Biol Chem 1992;267:4364-4369.

40. Van der Jagt DL, Kolb NS, Van der Jagt TJ, et al. Substrate specificity of human aldose reductase: identification of 4-hydroxynonenal as an endogenous substrate. Biochim Biophys Acta 1995;1249:117-126.

41. Inazu N, Nagashima Y, Satoh T, Fugi T. Purification and properties of six aldo-keto reductases from rat adrenal gland. J Biochem 1994;115:991-999.

42. Bohren KM, Bullock B, Gabbays KH. The aldo-keto reductase superfamily. J Bio Chem 1989;264:9547-9551.

43. Chung S, La Mendola J. Cloning and sequence determination of human placental aldose reductase gene. J Biol Chem 1989;264:14,775-14,777.

44. Nishimura C, Matsuura Y, Kokai Y, et al. Cloning and expression of human aldose reductase. J Biol Chem 1990;265:9788-9792.

45. Graham A, Brown L, Hedge PJ, Gammack AJ, Markham AF. Structure of the human aldose reductase gene. J Biol Chem 1991;266:6872-6877.

46. Bateman JB, Kojis T, Heinzmann C, et al. Mapping of aldose reductase gene sequences to human chromosomes 1, 3, 7, 9, 11, and 13. Genomics 1993;17:560-565.

47. Ko BCB, Ruepp B, Bohren KM, Gabbay KH, Chung SSM. Identification and characterisation of multiple osmotic response sequences in the human aldose reductase gene. J Biol Chem 1997;272:16,431-16,437.

48. Lopez-Rodriguez C, Aramburu J, Rakeman AS, Rao R. NFAT, a constitutively expressed nuclear NFAT protein that does not co-operate with Fos and Jun. Biochemistry 1999;96:7214-7219.

49. Iwata T, Sato S, Jimenez J, et al. Osmotic response element is required for the induction of aldose reductase by tumour necrosis factor-alpha. J Biol Chem 1999;274:7993-8001.

50. Aida K, Tawata M, Ikegishi Y, Onaya T. Induction of rat aldose reductase gene transcription is mediated through cis-element, osmotic response element (ORE): increased synthesis and/or activation by phosphorylation of ORE-binding protein is a key step. Endocrinology 1999;140:609-617.

51. Hodgkinson AD, Sondergaard KL, Yang B, Cross DF, Millward BA, Demaine AG. Aldose reductase expression is induced by hyperglycaemia in diabetic nephropathy. Kidney Int 2001;60:211-218.

52. Henry DN, Frank RN, Hootman SR, Rood SE, Helig CW, Busik JV. Glucose-specific regulation of aldose reductase in human retinal pigment epithelial cells in vitro. Invest Opthal Vis Sci 2000;41:1554-1560.

53. Maekawa K, Tanimoto T, Okada S, Susuki T, Suzuki T, Yabe-Nichimura C. Expression of aldose reductase and sorbitol dehydrogenase genes in Schwann cells isolated from rats: effects of high glucose and osmotic stress. Mol Brain Res 2001;87:251-256.

54. Patel A, Hibberd ML, Millward BA, Demaine AG. Chromosome 7q35 and susceptibility to diabetic microvascular complications. J Diabetic Compl 1996;10:62-67.

55. Li Q, Xie P, Huang J, Gu Y, Zeng W, Song H. Polymorphisms and functions of the aldose reductase gene 5 regulatory region in Chinese patients with type 2 diabetes mellitus. Chin Med J 2002;115:209-213.

56. Ko BCB, Lam KSL, Wat NMS, Chung SSM. An (A-C)n dinucleotide repeat polymorphic marker at the 5 end of the aldose reductase gene is associated with early onset diabetic retinopathy in NIDDM patients. Diabetes 1995;44:727-732.

57. Heesom AE, Hibberd ML, Millward BA, Demaine AG. Polymorphisms in the 5' end of the aldose reductase gene is strongly associated with the development of diabetic nephropathy in type 1 diabetes. Diabetes 1997;46:287-291.

58. Demaine A, Cross D, Millward A. Polymorphisms of the aldose reductase gene and susceptibility to retinopathyin type 1 diabetes mellitus. Invest Ophthalmol Vis Sci 2000; 41:4064-4068.

59. Fujisawa T, Ikegami H, Kawaguchi Y, et al. Length rather than a specific allele of dinu-cleotide repeat in the 5 upstream region of the aldose reductase gene is associated with diabetic retinopathy. Diabet Med 1999;16:1044-1047.

60. IkegishiY, Tawata M, Aida K, Onaya T. Z-4 allele upstream of the aldose reductase gene is associated with proliferative retinopathy in Japanese patients with NIDDM, and elevated luciferase gene transcription in vitro. Life Sci 1999;65:2061-2070.

61. Lee SC, Wang Y, Ko GT, et al. Association of retinopathy with a microsatellite at 5'end of the aldose reductase gene in Chinese patients with late-onset type 2 diabetes. Opthal Genetic 2001;22:63-67.

63. Kao YL, Donaghue K, Chan A, Knight J, Silink M. A novel polymorphism in the aldose reductase gene promoter region is strongly associated with diabetic retinopathyin adolescents with type 1 diabetes. Diabetes 1999;48:1338-1340.

64. Kao YL, Donaghue K, Chan A, Knight J, Silink M. An aldose reductase intragenic polymorphism associated with diabetic retinopathy. Diabetes Res Clin Prac 1999;46:155-160.

65. Maeda S, Haneda M, Yasuda H, et al. Diabetic nephropathy is not associated with the din-ucleotide repeat polymorphism upstream of the aldose reductase (ALR2) gene but with erythrocyte aldose reductase content in Japanese subjects with type 2 diabetes. Diabetes 1999;48:420-422.

66. Moczulski DK, Burak W, Doria A, Zukowska-Szczechowska E, Warram JH, Grzeszczak W. The role of aldose reductase in the susceptibility to diabetic nephropathy in type II (noninsulin dependent) diabetes mellitus. Diabetologia 1999;42:94-97.

67. Neamat-Allah M, Feeney SA, Savage DA, et al. Analysis of the association between diabetic nephropathy and polymorphisms in the aldose reductase gene in type 1 and type 2 diabetes mellitus. Diabet Med 2001;18:906-914.

68. Sivenius K, Niskanen L, Pihlajamaki J, Laakso M, Partanen J, Uusitupa M. Aldose reduc-tase gene polymorphisms and peripheral nerve function in patients with type 2 diabetes. Diabetes care 2004;27:2021-2026.

69. Shah VO, Dorin RI, Braun SM, Zager PG. Aldose reductase gene expression is increased in diabetic nephropathy. J Clin Endo Metab 1997;82:2294-2298.

70. Shah VO, Scavini M, Nikolic J, et al. Z-2 microsatellite allele is linked to increased expression of the aldose reductase gene in diabetic nephropathy. J Clin Endo Metab 1998;83: 2886-2891.

71. Yang BM, Millward A, Demaine A. Functional differences between the susceptibility Z-2/C-106 and protective Z+2/T-106 promoter region polymorphisms of the aldose reduc-tase gene may account for the association with diabetic microvascular complications. Biochm Biophys Acta 2003;1639:1-7.

72. Araki SI, Daniel PK, Ng K. Identification of a common risk haplotype for diabetic nephropathy at the protein kinase C-ß1 (PKCB1) gene locus. J Am Soc Nephrol 2003; 14:2015-2024.

73. Hammes HP, Martin S, Federlin K, Geisen K, Brownlee M. Aminoguanidine treatment inhibits the development of experimental diabetic retinopathy. Proc Natl Acad Sci 1991;88:11,555-11,558.

74. Soulis-Liparota T, Cooper M, Papazoglou D, Clarke B, Jerums G. Retardation by aminoguanidine of development of albuminuria, mesangial expansion, and tissue fluorescence in streptozocin-induced diabetic rat. Diabetes 1991;40:1328-1334.

75. Misur I, Zarkovic K, Barada A, Batelja L, Milicevic Z, Turk Z. Advanced glycation endprod-ucts in peripheral nerve in type 2 diabetes with neuropathy. Acta Diabetol 2004;41:158-166.

76. Mattson MP, Camandola S. NF-kappaB in neuronal plasticity and neurodegenerative disorders. J Clin Invest 2001;107:247-254.

77. Bierhaus A, Schiekofer S, Schwaninger M, et al. Diabetes-associated sustained activation of the transcription factor nuclear factor-kappaB. Diabetes 2001;50:2792-2808.

78. Bierhaus A, Haslbeck KM, Humpert PM, et al. Loss of pain perception in diabetes is dependent on a receptor of the immunoglobulin superfamily. J Clin Invest 2004;114:1741-1751.

79. Haslbeck KM, Bierhaus A, Erwin S, et al. Receptor for advanced glycation endproduct (RAGE)-mediated nuclear factor-kappaB activation in vasculitic neuropathy. Muscle Nerve 2004;29:853-860.

80. Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994;331: 1480-1487.

81. Gröne HJ. Angiogenesis and vascular endothelial growth factor (VEGF): is it relevant in renal patients? Nephrology Dialysis Transplantation 1995;10:761-763.

82. Williams B. Factors regulating the expression of vascular permeability/vascular endothe-lial growth factor by human vascular tissue. Diabetologia 1997;40(Suppl 2):118-120.

83. Shweki D, Itin A, Soffer D, Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 1992;359:843-845.

84. Samii A, Unger J, Lange W. Vascular endothelial growth factor expression in peripheral nerves and dorsal root ganglia in diabetic neuropathy in rats. Neurosci Lett 1999; 262:159-162.

85. Isner JM, Ropper A, Hirst K. VEGF gene transfer for diabetic neuropathy. Hum Gene Ther 2001;12:1593-1594.

86. Schratzberger P, Walter DH, Rittig K, et al. Reversal of experimental diabetic neuropathy by VEGF gene transfer. J Clin Invest 2001;107:1083-1092.

87. Yang BM, Cross DF, Ollerenshaw M, Millward BA, Demaine AG. Polymorphisms of vascular endothelial growth factor and susceptibility to diabetic microvascular complications in patients with type 1 diabetes mellitus. J Diabetes Compl 2003;17:1-6.

88. Hodgkinson AD, Millward BA, Demaine AG. Association of the p22phox component of NAD(P)H oxidase with susceptibility to diabetic nephropathy in patients with type 1 diabetes. Diabetes Care 2003;26:3111-3115.

89. Vincent AM, Olzmann JA, Brownlee M, Sivitz WI, Russell JW. Uncouping proteins prevent glucose-induced neuronal oxidative stress and programmed cell death. Diabetes 2004; 53:726-734.

90. Sima AA. New insights into the metabolic and molecular basis for diabetic neuropathy. Cell Mol Life Sci 2003;60(11):2445-2464.

91. Vague P, Coste TC, Jannot MF, Raccah D, Tsimaratos M. C-peptide, Na+/K(+)-ATPase, and diabetes. Exp Diabesity Res 2004;5:37-50.

92. Vague P, Dufayet D, Coste T, Moriscot C, Jannot MF, Raccah D. Association of diabetic neuropathy with Na/K ATPase gene polymorphism. Diabetologia 1997;40(5):506-511.

93. Jannot MF, Raccah D, De La Tour DD, Coste T, Vague P. Genetic nad environmental regulation of Na/K adenosine triphosphotase activity in diabetic patients. Metabolism 2002;51(3):284-291.

94. Leinninger GM, Vincent AM, Feldman EL. The role of growth factors in diabetic peripheral neuropathy. J Peripher Nerv Syst 2004;9:26-53.

95. Brewster WJ, Femyhough P, Diemel LT, Mohiuddin L, Tomlinson DR. Diabetic neuropathy, nerve growth factor and other neurotrophic factors. Trends Neurosci 1994;17:321-325.

96. Fernyhough P, Diemel LT, Hardy J, Brewster WJ, Mohiuddin L, Tomlinson DR. Human recombinant nerve growth factor replaces deficient neurotrophic support in the diabetic rat. Eur J Neurosci 1995;7:1107-1110.

97. Obrosova IG, Li F, Abatan OI, et al. Role of poly(ADP-ribose) polymerase activation in diabetic neuropathy. Diabetes 2004;53:711-720.

98. Garcia Soriano F, Virag L, Jagtap P, et al. Diabetic endothelial dysfunction: the role of poly (ADP-ribose) polymerase activation. Nat Med 2001;7:108-113.

99. Pacher P, Liaudet L, Soriano FG, Mabley JG, Szabo E, Szabo C. The role of poly(ADP-ribose) polymerase activation in the development of myocardial and endothelial dysfunction in diabetes. Diabetes 2002;51(2):514-521.

100. Virag L, Szabo C. The therapeutic potential of poly(ADP-ribose) polymerase inhibitors. Pharmacol Rev 2002;54:375-429.

101. Yu SW, Wang H, Poitras MF, et al. Mediation of poly(ADP-ribose) polymerase-1-dependent cell death by apoptosis-inducing factor. Science 2002;297:259-263.

102. Soriano FG, Virag L, Szabo C. Diabetic endothelial dysfunction: role of reactive oxygen and nitrogen species production and poly(ADP-ribose) polymerase activation. J Mol Med 2001;79:437-448.

103. Berciano MT, Fernandez R, Pena E, Calle E, Villagra NT, Lafarga M. Necrosis of Schwann cells during tellurium-induced primary demyelination: DNA fragmentation, reorganization of splicing machinery, and formation of intranuclear rods of actin. Neuropathol Exp Neurol 1999;58:1234-1243.

104. Heesom AE, Millward A, Demaine AG. Susceptibility to diabetic neuropathy in patients with insulin dependent diabetes mellitus is associated with a polymorphism at the 5' end of the aldose reductase gene. J Neurol Neurosurg Psychiatry 1998;64:213-216.

105. Ng DP, Conn J, Chung SS, Larkins RG. Aldose reductase (AC)n microsatellite polymorphism and diabetic microvascular complications in Caucasian type 1 diabetes mellitus. Diabetes Res Clin Prac 2001;52:21-27.

106. Ichikawa F, Yamada K, Ischiyama-Shigemotu S, Yuan X, Nonaka K. Association of an (A-C)n dinucleotide repeat polymorphic marker at the 5'-region of the aldose reductase gene with retinopathy but not with nephropathy or neuropathy in Japanese patients with Type 2 diabetes mellitus. Diabet Med 1999;16:744-748.

107. Moczulski DK, Burak W, Doria A, et al. The role of aldose reductase gene in the susceptibility to diabetic nephropathy in Type II (non-insulin-dependent) diabetes mellitus. Diabetologia 1999;42:94-97.

108. Olmos P, Futers S, Acosta AM, et al. (AC)23 [Z-2] polymorphism of the aldose reductase gene and fast progression of retinopathy in Chilcan type 2 diabetics. Diabetes Res Clin Pract 2000;47:169-176.

109. Strokov IA, Bursa TR, Drepa OI, Zotova EV, Nosikov VV, Ametov AS. Predisposing genetic factors for diabetic polyneuropathy in patients with type 1 diabetes: a population-based case-control study. Acta Diabetol 2003;40(Supp 2):S375-379.

110. Letellier C, Durou MR, Jouanolle AM, Le Gall JY, Poirier JY, Ruelland A. Serum paraox-onase activity and paraoxonase gene polymorphism in type 2 diabetic patients with or without vascular complications. Diabetes Metab 2002;28:297-304.

111. Bedlack RS, Strittmatter WJ, Morgenlander JC. Apolipoprotein E and neuromuscular disease: a critical review of the literature. Arch Neurol 2000;57:1561-1565.

112. Bedlack RS, Edelman D, Gibbs JW 3rd, et al. APOE genotype is a risk factor for neuropathy severity in diabetic patients. Neurology 2003;60:1022-1024.

113. Murata M, Maruyama T, Suzuki Y, Ikeda Y. Paraoxonase 1 192Gln/Arg polymorphism is associated with the risk of microangiopathy in type 2 diabetes mellitus. Diabetic Med 2004;21:837-844.

114. Chistyakov DA, Savost'anov KV, Zotova EV, Nosikov VV. Polymorphisms in the Mn-SOD and EC-SOD genes and their relationship to diabetic neuropathy in type 1 diabetes mellitus. BMC Med Genet 2001;2:4.

115. Ye L, Xu Y, Zhu Y, Fan Y, Deng H, Zhang J. Association of polymorphism in neurogenic differentiation factor 1 gene with type 2 diabetes. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 2002;19:484-487.

116. Zotova EV, Savost'ianov KV, Chistiakov DA, et al. Search for the association of polymorphic markers for genes coding for antioxidant defence enzymes, with development of diabetic polyneuropathies in patients with type 1 diabetes mellitus. Mol Biol (Mosk) 2004;38:244-249.

117. Nosikov VV. Genomics of type 1 diabetes mellitus and its late complications. Mol Biol (Mosk) 2004;38:150-164.

118. Zotova EV, Chistiakov DA, Savost'ianov KV, et al. Association of the SOD2 Ala(-9)val and SOD3 Arg213Gly polymorphisms with diabetic polyneuropathy in patients with diabetes mellitus type 1. Mol Biol (Mosk) 2004;37:404-408.

119. Zhou Z, Hoke A, Cornblath DR, Griffin JW, Polydefkis M. APOE epsilon4 is not a susceptibility gene in idiopathic or diabetic sensory neuropathy. Neurology 2005;64(1):139-141.

120. Cai H, Wang X, Colagiuri S, Wilcken DEL. A common Glu298oAsp (849GoT) mutation at exon 7 of the endothelial nitric oxide synthase gene and vascular complications in type 2 diabetes. Diabetes Care 1998;21:2195-2196.

Shcherbak NS, Schwartz EI. The C825T polymorphism in the G-protein beta3 subunit gene and diabetic complications in IDDM patients. J Hum Genet 2001;46(1):188-191. Asada T, Takakura S, Ogawa T, Iwai M, Kobayashi M. Overexpression of glucose transport protein 5 in sciatic nerve of streptozotocin-induced diabetic rats. Neurosci Lett 1998;14:111-114.

Cai F, Tomlinson DR, Fernyhough P. Elevated expression of neurotrophin-3 mRNA in sensory nerve of streptozotocin-diabetic rats. Neurosci Lett 1999;263:81-84. Shimizu H, Ohtani KI, Tsuchiya T, et al. Aldose reductase mRNA expression is associated with rapid development of diabetic microangiopathy in Japanese Type 2 diabetic (T2DM) patients. Diabetes Nutr Metab 2000;l3:75-79.

Xu G, Sima AA. Altered immediate early gene expression in injured diabetic nerve: implications in regeneration. J Neuropathol Exp Neurol 2001;60:972-983. Pittenger G, Vinik A. Nerve growth factor and diabetic neuropathy. Exp Diabesity Res 2003;4:271-285.

Matsuda M, Kawasaki F, Inoue H, et al. Possible contribution of adipocytokines on diabetic neuropathy. Diabet Res Clin Pract 2004;66(Suppl 1):S121-S123. Wright DE, Ryals JM, McCarson KE, Christianson JA. Diabetes-induced expression of activating transcription factor 3 in mouse primary sensory neurons. J Perpher Nerv Syst 2004;8:242-254.

Sozmen EY, Sozmen B, Delen Y, Onat T. Catalase/superoxide dismutase (SOD) and cata-lase/paraoxonase (PON) ratios may implicate poor glycemic control. Arch Med Res 2001;32:283-287.

Harjutsalo V, Katoh S, Sarti C, Tajima N, Tuomilehto J. Population-based assessment of familial clustering of diabetic nephropathy in type 1 diabetes. Diabetes 2004;53(9):2449-2454. Kasajima H, Yamagishi S, Sugai S, Yagihashi N, Yagihashi S. Enhanced in situ expression of aldose reductase in peripheral nerve and renal glomeruli in diabetic patients. Virchows Arch 2001;439(1):46-54.

Murthy KG, Salzman AL, Southan GJ, Szabo C. Diabetic endothelial dysfunction: the role of poly(ADP-ribose) polymerase activation. Nat Med 2001;7:108-113.

Rossell JW, Golovov D, Vincent AM, et al. High glucose-induced oxidative trsess and mitochondrial dysfunction in neurons. FASEB J 2002;16:1738-1748.

Samaii A, Unger J, Lange W. Vascular endothelial growth factor expression in peripheral nerves and dorsal root ganglia in diabetic neuropathy in rats. Neurosci Lett 1999;


Schimizu H, Ohtani KI, Tsuchiya T, et al. Aldose reductase mRNA expression is associated with rapid development of diabetic microangiopathy in Japanese type 2 diabetic (T2DM) patients. Diabetes Nutr Metab 2000;13:75-79.

Shangguan Y, Hall KE, Neubig RR, Wiley JW. Diabetic neuropathy: inhibitory G protein dysfunction involves PKC-dependent phosphorylation of Goalpha. Neurochemistry 2003; 86(4):1006-1014.

UK Prospective Diabetes Study (UKPDS) Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes. Brit Med J 1998; 317:703.

UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-853.

Pirart J. Diabetes mellitus and its degenerative complications: a prospective study of 4,400

patients observed between 1947 and 1973. Diabetes Metab 1997;3:97-107.

Zochodne DW. Diabetic neuropathies: features and mechanisms. Brain Pathol 1999;9:

Peripheral Neuropathy Natural Treatment Options

Peripheral Neuropathy Natural Treatment Options

This guide will help millions of people understand this condition so that they can take control of their lives and make informed decisions. The ebook covers information on a vast number of different types of neuropathy. In addition, it will be a useful resource for their families, caregivers, and health care providers.

Get My Free Ebook

Post a comment